[Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008].
METHODS
Despite the increasing prevalence of malignant melanoma, psychosocial aspects have found little attention. A systematic review was conducted in order to identify psycho-oncological articles on patients with malignant melanoma.


RESULTS
Out of a total of 31 studies, 12 examine quality of life in malignant melanoma patients and 6 studies monitor quality of life in the course of therapy. Most studies originate from English-speaking countries (USA, UK, AU); few German studies have been published. Methodological limitations of the studies include cross-sectional assessment, unreported return rate, small sample sizes and comparability (heterogeneous or non-standardized psychosocial measures).


CONCLUSIONS
In addition to the tumor stage, psychosocial characteristics (coping with disease, social support) have a substantial effect on quality of life. Results from psychotherapy trials with malignant melanoma patients are encouraging. Given the overall high survival rates of malignant melanoma, quality of life and needs for care of long-term survivors need to be assessed.
Beutel
M E
ME
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin Mainz, Untere Zahlbacher Str. 8, 55131, Mainz. Beutel@Psychosomatik.Klinik.Uni-Mainz.de
Blettner
M
M
Fischbeck
S
S
Loquay
C
C
Werner
A
A
Marian
H
H
D015897:Comorbidity; D006801:Humans; D038622:Internationality; D008545:Melanoma / Q000453:epidemiology* / Q000523:psychology*; D001523:Mental Disorders / Q000453:epidemiology* / Q000523:psychology*; D015995:Prevalence; D011788:Quality of Life; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000523:psychology*
J Am Acad Dermatol. 2005 Aug;53(2):224-9
16021114
Psychooncology. 2004 Aug;13(8):526-36
15295774
Hautarzt. 2008 Jun;59(6):484-91
18478195
J Cutan Med Surg. 2004 Sep-Oct;8(5):303-9
15868284
N Engl J Med. 2001 Mar 29;344(13):961-6
11274622
Ann Oncol. 2005 May;16(5):805-16
15817599
Psychosomatics. 1999 May-Jun;40(3):239-50
10341537
Support Care Cancer. 2003 May;11(5):304-12
12720074
J Clin Oncol. 1999 Jul;17(7):2256-63
10561283
J Dtsch Dermatol Ges. 2004 Feb;2(2):105-10
16279244
Melanoma Res. 2002 Oct;12(5):505-11
12394193
Psychooncology. 1999 Jan-Feb;8(1):27-35
10202780
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1969-76
17035407
Hautarzt. 2004 Aug;55(8):735-45
15241519
Br J Cancer. 2006 Feb 27;94(4):492-8
16449995
J Clin Oncol. 2007 Dec 20;25(36):5698-703
18089864
Eur J Surg Oncol. 2007 Aug;33(6):776-82
17300914
J Behav Med. 2006 Oct;29(5):419-34
16855870
Psychother Psychosom Med Psychol. 2003 Jun;53(6):258-66
12813660
Qual Life Res. 1993 Jun;2(3):193-203
8401455
Arch Gen Psychiatry. 2003 Jan;60(1):100-3
12511177
Psychooncology. 2007 Apr;16(4):287-94
16858669
Cancer. 2003 Aug 15;98(4):854-64
12910531
Int J Cancer. 2000 May 20;89(3):271-9
10861504
Psychosom Med. 2007 Sep-Oct;69(7):667-74
17766690
J Cancer Surviv. 2007 Mar;1(1):87-97
18648948
Br J Cancer. 2000 Dec;83(11):1448-53
11076652
Z Psychosom Med Psychother. 2009;55(4):365-81
20229484
J Investig Dermatol Symp Proc. 2004 Mar;9(2):152-9
15083783
J Clin Oncol. 2001 Jun 1;19(11):2844-50
11387356
Psychooncology. 1999 Jan-Feb;8(1):14-26
10202779
BMC Cancer. 2006 Apr 18;6:95
16620390
J Clin Oncol. 2004 Mar 15;22(6):1118-25
15020614
Lancet Oncol. 2005 Aug;6(8):608-21
16054572
J Psychosom Res. 2007 Jul;63(1):9-15
17586333
J Psychosom Res. 2005 Jan;58(1):19-27
15771866